MA30631B1 - Inhibiteurs de tyrosine kinase - Google Patents

Inhibiteurs de tyrosine kinase

Info

Publication number
MA30631B1
MA30631B1 MA31620A MA31620A MA30631B1 MA 30631 B1 MA30631 B1 MA 30631B1 MA 31620 A MA31620 A MA 31620A MA 31620 A MA31620 A MA 31620A MA 30631 B1 MA30631 B1 MA 30631B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitors
met
treating
cyclohepta
Prior art date
Application number
MA31620A
Other languages
English (en)
Inventor
Christopher J Dinsmore
Matthew H Katcher
Alan B Northrup
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30631B1 publication Critical patent/MA30631B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des dérivés de 5H-benzo[4,5]cyclohepta [1,2-b]pyridine, qui sont utiles pour traiter des maladies de prolifération cellulaire, pour traiter les troubles associés à l'activité de MET, et pour l'inhibition du récepteur tyrosine kinase MET. L'invention concerne aussi des compositions qui comprennent ces composés, et des procédés pour les utiliser pour traiter le cancer chez des mammifères.
MA31620A 2006-07-10 2009-02-09 Inhibiteurs de tyrosine kinase MA30631B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81976406P 2006-07-10 2006-07-10

Publications (1)

Publication Number Publication Date
MA30631B1 true MA30631B1 (fr) 2009-08-03

Family

ID=38923821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31620A MA30631B1 (fr) 2006-07-10 2009-02-09 Inhibiteurs de tyrosine kinase

Country Status (24)

Country Link
US (2) US8222269B2 (fr)
EP (1) EP2049494B1 (fr)
JP (2) JP4203121B1 (fr)
KR (1) KR20090026187A (fr)
CN (1) CN101535268B (fr)
AR (1) AR061804A1 (fr)
AU (1) AU2007273081B2 (fr)
BR (1) BRPI0713941A2 (fr)
CA (1) CA2656578C (fr)
CO (1) CO6190518A2 (fr)
CR (1) CR10560A (fr)
EC (1) ECSP099051A (fr)
ES (1) ES2497493T3 (fr)
GT (1) GT200900004A (fr)
HN (1) HN2009000018A (fr)
IL (1) IL196337A0 (fr)
MA (1) MA30631B1 (fr)
MX (1) MX2009000410A (fr)
NO (1) NO20090608L (fr)
PE (1) PE20080275A1 (fr)
RU (1) RU2009104303A (fr)
TW (1) TW200813021A (fr)
WO (1) WO2008008310A2 (fr)
ZA (1) ZA200900019B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2408584C2 (ru) 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
BRPI0912826A2 (pt) * 2008-05-21 2015-07-28 Basf Se Uso de compostos, composições agroquímicas, método para combater fungos fitopatogênicos, semente, compostos, e, processo para preparar compostos
US8674105B2 (en) 2009-09-30 2014-03-18 Merck Sharp & Dohme Limited Crystalline hydrochloride salts of c-Met kinase inhibitors
US9238571B2 (en) * 2009-09-30 2016-01-19 Merck Sharp & Dohme Limited Formulations for c-Met kinase inhibitors
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
EP2588107A1 (fr) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
WO2015017528A1 (fr) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Fusions de pik3c2g
EP3628749A1 (fr) * 2013-07-30 2020-04-01 Blueprint Medicines Corporation Fusions de ntrk2
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
US11369618B2 (en) * 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (fr) 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU700386B2 (en) 1995-10-16 1999-01-07 Kyowa Hakko Kogyo Co. Ltd. Triciclic compounds
CN1104428C (zh) 1996-09-13 2003-04-02 先灵公司 用作法呢基－蛋白转移酶抑制剂的取代的苯并芳庚并吡啶
CA2264569C (fr) 1996-09-13 2003-11-11 Schering Corporation Composes tricycliques inhibant la fonction de la proteine g et traitant les maladies proliferantes
CA2460939C (fr) 2001-09-19 2008-07-29 Pharmacia Corporation Composes de pyrazolyl substitues pour le traitement de l'inflammation
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
WO2006014420A1 (fr) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Modulateurs quinazoline d'activite de facteur de croissance hepatocyte/c-met permettant de traiter le cancer
TW200738638A (en) * 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
RU2408584C2 (ru) * 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы

Also Published As

Publication number Publication date
EP2049494A2 (fr) 2009-04-22
CA2656578C (fr) 2012-09-04
JP4203121B1 (ja) 2008-12-24
AU2007273081A1 (en) 2008-01-17
WO2008008310A2 (fr) 2008-01-17
ECSP099051A (es) 2009-02-27
US8222269B2 (en) 2012-07-17
MX2009000410A (es) 2009-01-27
ES2497493T3 (es) 2014-09-23
CN101535268B (zh) 2012-11-14
JP5245045B2 (ja) 2013-07-24
AR061804A1 (es) 2008-09-24
BRPI0713941A2 (pt) 2012-12-04
GT200900004A (es) 2010-04-13
JP2009173622A (ja) 2009-08-06
KR20090026187A (ko) 2009-03-11
ZA200900019B (en) 2009-11-25
EP2049494B1 (fr) 2014-06-25
PE20080275A1 (es) 2008-04-03
WO2008008310A3 (fr) 2008-05-15
US20090203684A1 (en) 2009-08-13
CA2656578A1 (fr) 2008-01-17
CR10560A (es) 2009-02-26
AU2007273081B2 (en) 2011-04-07
NO20090608L (no) 2009-04-14
JP2009512698A (ja) 2009-03-26
US20090012076A1 (en) 2009-01-08
TW200813021A (en) 2008-03-16
RU2009104303A (ru) 2010-08-20
HN2009000018A (es) 2011-01-24
US8101603B2 (en) 2012-01-24
CN101535268A (zh) 2009-09-16
CO6190518A2 (es) 2010-08-19
IL196337A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
WO2008008310A3 (fr) Inhibiteurs de la tyrosine kinase
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met
WO2007149427A3 (fr) Inhibiteurs de tyrosine kinase
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
YU84603A (sh) Novi inhibitori tirozin kinaze
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines
EP1463733A4 (fr) Inhibiteurs de kinesine mitotique
WO2003049678A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2003049679A3 (fr) Inhibiteurs mitotiques de la kinésine
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2003039460A3 (fr) Inhibiteurs de la kinesine mitotique
WO2006124354A3 (fr) Inhibiteurs de la tyrosine kinase
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
WO2004058148A3 (fr) Inhibiteurs de la kinesine mitotique
WO2005060654A3 (fr) Inhibiteurs de kinesines mitotiques
WO2007095223A3 (fr) PYRROLO(3,2-C) PYRIDINES utiles en tant qu'inhibiteurs de proteines-kinases
MA29561B1 (fr) DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2007118151A3 (fr) Dérivés spirocycliques hétérocycliques et procédés pour leur utilisation
MXPA04010307A (es) Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion.
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
WO2006068933A3 (fr) Inhibiteurs de la kinesine mitotique
WO2007050380A3 (fr) Inhibiteurs de la tyrosine kinase